Consensus Enovis Corporation

Stocks

ENOV

US1940145022

Medical Equipment, Supplies & Distribution

Market Closed - NYSE Other stock markets 00:00:02 18/07/2026 +04			5-day change	1st Jan Change
27.07 ^USD	-3.56%		+5.13%	+1.61%

07-13	Enovis Corporation Launches Ct-Revitl Laser Therapy System for Veterinary Care	CI
07-09	BMO Capital Initiates Enovis at Outperform With $29 Price Target	MT

Evolution of the Average Target: Enovis Corporation

Evolution of the Target Price: Enovis Corporation

Changes in Analyst Recommendations: Enovis Corporation

0099d44.Bk5PQC4ioyTkT7lqnrIqhjTM57pniWY2s3i3fhwyhVM.f30AJ3l9wUHcCtEk-NFfxwCht8wxuDYb8D-DOGh64DpNCQcyRE-Saoca3g~d1dc09d9ea27d89be2d4ea489ef3990d

Analysts' recommendations: Enovis Corporation

07-09	BMO Capital Initiates Enovis at Outperform With $29 Price Target	MT
02-27	Needham Raises Price Target on Enovis to $52 From $49, Keeps Buy Rating	MT
01-06	BTIG Initiates Enovis at Buy With $41 Price Target	MT
08/08/25	Needham Cuts Price Target on Enovis to $49 From $57, Keeps Buy Rating	MT
08/08/25	UBS Adjusts Enovis Price Target to $57 From $65, Maintains Buy Rating	MT
12/05/25	UBS Adjusts Price Target on Enovis to $65 From $75, Maintains Buy Rating	MT
03/10/24	JMP Securities Initiates Enovis at Outperform With $62 Price Target	MT
08/08/24	Needham Adjusts Price Target on Enovis to $65 From $82, Maintains Buy Rating	MT
13/06/24	JPMorgan Initiates Enovis at Neutral With $53 Price Target	MT
23/02/24	Canaccord Genuity Ups Price Target on Enovis to $75 From $73, Maintains Buy Rating	MT
23/02/24	Needham Raises Price Target on Enovis to $82 From $73, Maintains Buy Rating	MT
13/02/24	Stephens Initiates Enovis With Overweight Rating, $72 Price Target	MT
22/01/24	UBS Initiates Coverage on Enovis With Buy Rating, $75 Price Target	MT
03/01/24	William Blair Initiates Enovis at Outperform Rating	MT
20/12/23	Canaccord Genuity Adjusts Enovis Price Target to $71 From $65, Maintains Buy Rating	MT
15/12/23	Needham Adjusts Price Target on Enovis to $70 From $62, Keeps Buy Rating	MT
04/08/23	Baird Adjusts Price Target on Enovis to $70 From $67, Maintains Outperform Rating	MT
26/06/23	Needham Initiates Enovis With Buy Rating, $70 Price Target	MT
12/05/23	Wells Fargo Upgrades Enovis to Overweight Rating From Equal Weight, Adjusts Price Target to $67 From $55	MT
24/02/23	Baird Adjusts Enovis Price Target to $64 From $68, Maintains Outperform Rating	MT
03/11/22	Baird Adjusts Enovis' Price Target to $68 From $73, Keeps Outperform Rating	MT
26/10/22	Wells Fargo Lowers Enovis' Price Target to $53 From $60, Keeps Equalweight Rating	MT
12/10/22	Jefferies Initiates Enovis at Buy with $60 Price Target	MT
11/10/22	Goldman Sachs Initiates Coverage on Enovis With Buy Rating, $57 Price Target	MT
12/09/22	Evercore ISI Starts Enovis at Outperform With $68 Price Target	MT

More recommendations

Sector Comparison:

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
ENOVIS CORPORATION			+50.45%
STRYKER CORPORATION			+20.84%
SMITH & NEPHEW PLC			+18.15%
GLAUKOS CORPORATION			+5.21%
IMEIK TECHNOLOGY DEVELOPMENT CO.,LTD.			+46.52%
DOUBLE MEDICAL TECHNOLOGY INC.	-	-	+16.33%
BEIJING BALANCE MEDICAL TECHNOLOGY CO.,LTD.	-	-	-
SHANGHAI MICROPORT ENDOVASCULAR MEDTECH CO., LTD.			+41.89%
INSPIRE MEDICAL SYSTEMS, INC.			+3.53%
Average			+25.36%
Weighted average by Cap.			+20.70%

See all sector consensus

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

27.07USD

Average target price

40.73USD

Spread / Average Target

+50.45%

High Price Target

55.00USD

Spread / Highest target

+103.18%

Low Price Target

29.00USD

Spread / Lowest Target

+7.13%

Analyst Consensus Detail

Consensus revision (last 18 months)

Analysts covering the company

BMO Capital
Needham & Co.
BTIG
UBS
JMP Securities
JPMorgan Chase
Canaccord Genuity
Stephens Inc.
William Blair & Co.
Baird
Wells Fargo Securities
Jefferies & Co.
Goldman Sachs
Evercore ISI
Argus
Loop Capital
Morgan Stanley
KeyBanc Capital Markets
Stifel Nicolaus
Seaport Global Securities
Deutsche Bank Securities
Barclays